177 related articles for article (PubMed ID: 1698995)
1. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro.
Robinson WE; Kawamura T; Lake D; Masuho Y; Mitchell WM; Hersh EM
J Virol; 1990 Nov; 64(11):5301-5. PubMed ID: 1698995
[TBL] [Abstract][Full Text] [Related]
2. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.
Robinson WE; Gorny MK; Xu JY; Mitchell WM; Zolla-Pazner S
J Virol; 1991 Aug; 65(8):4169-76. PubMed ID: 2072448
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of a common epitope responsible for the induction of antibody-dependent enhancement of HIV.
Mitchell WM; Ding L; Gabriel J
AIDS; 1998 Jan; 12(2):147-56. PubMed ID: 9468363
[TBL] [Abstract][Full Text] [Related]
4. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.
Robinson WE; Kawamura T; Gorny MK; Lake D; Xu JY; Matsumoto Y; Sugano T; Masuho Y; Mitchell WM; Hersh E
Proc Natl Acad Sci U S A; 1990 Apr; 87(8):3185-9. PubMed ID: 2326277
[TBL] [Abstract][Full Text] [Related]
5. Enhancing antibodies in HIV infection.
Füst G
Parasitology; 1997; 115 Suppl():S127-40. PubMed ID: 9571698
[TBL] [Abstract][Full Text] [Related]
6. Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies.
Lopalco L; Longhi R; Ciccomascolo F; De Rossi A; Pelagi M; Andronico F; Moore JP; Schulz T; Beretta A; Siccardi AG
AIDS Res Hum Retroviruses; 1993 Jan; 9(1):33-9. PubMed ID: 7678970
[TBL] [Abstract][Full Text] [Related]
7. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
8. Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41.
Cavacini LA; Emes CL; Wisnewski AV; Power J; Lewis G; Montefiori D; Posner MR
AIDS Res Hum Retroviruses; 1998 Sep; 14(14):1271-80. PubMed ID: 9764911
[TBL] [Abstract][Full Text] [Related]
9. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
Nyambi PN; Mbah HA; Burda S; Williams C; Gorny MK; Nádas A; Zolla-Pazner S
J Virol; 2000 Aug; 74(15):7096-107. PubMed ID: 10888650
[TBL] [Abstract][Full Text] [Related]
10. Confronting the hypervariability of an immunodominant epitope eliciting virus neutralizing antibodies from the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1).
Neurath AR; Strick N
Mol Immunol; 1990 Jun; 27(6):539-49. PubMed ID: 1696353
[TBL] [Abstract][Full Text] [Related]
11. Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: the envelope of the human immunodeficiency virus (HIV-1).
Neurath AR; Strick N; Jiang S
Virology; 1992 May; 188(1):1-13. PubMed ID: 1373549
[TBL] [Abstract][Full Text] [Related]
12. Anti-human immunodeficiency virus type 1 human monoclonal antibodies that bind discontinuous epitopes in the viral glycoproteins can identify mimotopes from recombinant phage peptide display libraries.
Boots LJ; McKenna PM; Arnold BA; Keller PM; Gorny MK; Zolla-Pazner S; Robinson JE; Conley AJ
AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1549-59. PubMed ID: 9430247
[TBL] [Abstract][Full Text] [Related]
13. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies.
Xu JY; Gorny MK; Palker T; Karwowska S; Zolla-Pazner S
J Virol; 1991 Sep; 65(9):4832-8. PubMed ID: 1714520
[TBL] [Abstract][Full Text] [Related]
14. Primary in vitro immunization with multimeric synthetic peptides of HIV-1 envelope glycoproteins: generation of neutralizing human monoclonal antibodies.
Fraisier C; Ebersold A; Blomberg J; Desgranges C
J Immunol Methods; 1994 Nov; 176(1):9-22. PubMed ID: 7963597
[TBL] [Abstract][Full Text] [Related]
15. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
[TBL] [Abstract][Full Text] [Related]
16. Complement activation by human monoclonal antibodies to human immunodeficiency virus.
Spear GT; Takefman DM; Sullivan BL; Landay AL; Zolla-Pazner S
J Virol; 1993 Jan; 67(1):53-9. PubMed ID: 7677959
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a mouse/human chimeric monoclonal antibody (C beta 1) to a principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.
Matsushita S; Maeda H; Kimachi K; Eda Y; Maeda Y; Murakami T; Tokiyoshi S; Takatsuki K
AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1107-15. PubMed ID: 1380258
[TBL] [Abstract][Full Text] [Related]
18. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
[TBL] [Abstract][Full Text] [Related]
19. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
Richardson TM; Stryjewski BL; Broder CC; Hoxie JA; Mascola JR; Earl PL; Doms RW
J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
[TBL] [Abstract][Full Text] [Related]
20. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
Alsmadi O; Tilley SA
J Virol; 1998 Jan; 72(1):286-93. PubMed ID: 9420226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
